• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Lexeo Therapeutics Inc.

    6/4/25 4:04:18 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $LXEO alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Lexeo Therapeutics, Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)


    52886X107

    (CUSIP Number)


    05/28/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    52886X107


    1Names of Reporting Persons

    Affinity Healthcare Fund, LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,252,005.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,252,005.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,252,005.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.75 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    52886X107


    1Names of Reporting Persons

    Affinity Asset Advisors, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,252,005.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,252,005.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,252,005.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.75 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Lexeo Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    345 Park Avenue South, Floor 6, New York, NY 10010
    Item 2. 
    (a)Name of person filing:

    Affinity Healthcare Fund, LP Affinity Asset Advisors, LLC
    (b)Address or principal business office or, if none, residence:

    450 Park Avenue Suite 1403 New York, NY 10022
    (c)Citizenship:

    Affinity Healthcare Fund, LP and Affinity Asset Advisors, LLC - Delaware
    (d)Title of class of securities:

    Common Stock, par value $0.0001 per share
    (e)CUSIP No.:

    52886X107
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Affinity Asset Advisors, LLC (the "Advisor") is the investment manager of Affinity Healthcare Fund, LP (the "Fund") and exercises investment discretion with regard to the securities reported herein. As of June 4, 2025, the Fund beneficially owned an aggregate of 4,252,005 shares of Common Stock of the Issuer, including warrants to purchase 867,302 shares of Common Stock within the next sixty (60) days, or 7.75% of the outstanding shares of Common Stock of the Issuer, and the Advisor may be deemed to be the beneficial owner of such 4,252,005 shares of Common Stock of the Issuer owned by the Fund by virtue of its position as investment manager of the Fund. The Fund and the Advisor have the shared power to vote or to direct the vote and to dispose or direct the disposition of 4,252,005 shares of Common Stock of the Issuer.
    (b)Percent of class:

    The percentage set forth in the preceding paragraph and in Row 11 of the cover page for each reporting person is based on 54,854,419 shares of Common Stock of the Issuer outstanding as of May 28, 2025 comprised of (a) the 33,196,997 shares of Common Stock of the Issuer outstanding as of May 12, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 15, 2025, (b) the 20,790,120 shares of Common Stock of the Issuer issued in connection with a private placement by the Issuer on May 28, 2025 as set forth in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 27, 2025 and (c) the 867,302 shares of Common Stock of the Issuer issuable to the Fund upon exercise of Common Warrants of the Issuer sold to the Fund in such private placement.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Affinity Healthcare Fund, LP - 0 Affinity Asset Advisors, LLC - 0

     (ii) Shared power to vote or to direct the vote:

    Affinity Healthcare Fund, LP - 4,252,005 Affinity Asset Advisors, LLC - 4,252,005

     (iii) Sole power to dispose or to direct the disposition of:

    Affinity Healthcare Fund, LP - 0 Affinity Asset Advisors, LLC - 0

     (iv) Shared power to dispose or to direct the disposition of:

    Affinity Healthcare Fund, LP - 4,252,005 Affinity Asset Advisors, LLC - 4,252,005

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Affinity Healthcare Fund, LP
     
    Signature:/s/ Andrew Weinstein
    Name/Title:Andrew Weinstein
    Date:06/04/2025
     
    Affinity Asset Advisors, LLC
     
    Signature:/s/ Andrew Weinstein
    Name/Title:Andrew Weinstein
    Date:06/04/2025
    Get the next $LXEO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LXEO

    DatePrice TargetRatingAnalyst
    6/13/2024$28.00Outperform
    Robert W. Baird
    6/6/2024$22.00Buy
    H.C. Wainwright
    11/28/2023$20.00Overweight
    JP Morgan
    11/28/2023$20.00Buy
    Stifel
    11/28/2023$19.00Outperform
    Leerink Partners
    11/28/2023$22.00Outperform
    RBC Capital Mkts
    11/28/2023$23.00Buy
    Chardan Capital Markets
    More analyst ratings

    $LXEO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Robert W. Baird initiated coverage on Lexeo Therapeutics with a new price target

      Robert W. Baird initiated coverage of Lexeo Therapeutics with a rating of Outperform and set a new price target of $28.00

      6/13/24 7:10:25 AM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright initiated coverage on Lexeo Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Lexeo Therapeutics with a rating of Buy and set a new price target of $22.00

      6/6/24 7:17:54 AM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JP Morgan initiated coverage on Lexeo Therapeutics with a new price target

      JP Morgan initiated coverage of Lexeo Therapeutics with a rating of Overweight and set a new price target of $20.00

      11/28/23 7:29:52 AM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LXEO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Lexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA Therapeutics

      Up to $40 Million Private Equity Financing into a New Entity Addressing Cardiac Genetic Diseases that Existing AAV Platforms are Unable to Treat Lexeo Contributing Expertise and Know-How in Cardiac Genetic Medicines, Preclinical Intellectual Property, and Technology, in Combination with Novel Non-Viral RNA Delivery Platform Represents Pipeline Diversification and Advancement of Leading-Edge Cardiovascular Science NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced a strategic partnership to develop therapies for genetic cardiac d

      6/24/25 7:30:00 AM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases

      Cash runway extended into 2028; capital proceeds to fund operations through potential 2027 efficacy readout for LX2006 in Friedreich ataxia cardiomyopathy Financing led by Frazier Life Sciences and Janus Henderson Investors with participation from new and existing investors NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced it has entered into a securities purchase agreement with a select group of institutional and healthcare accredited investors to issue and sell an aggregate of 20,790,120 shares ("Shares") of its common sto

      5/27/25 7:31:10 AM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights

      Announced positive interim data for LX2006 from Phase 1/2 studies in Friederich ataxia (FA) cardiomyopathy; frataxin expression and LVMI improvement exceeded co-primary target thresholds for planned registrational study LX2006 registrational study expected to begin by early 2026; commencing enrollment in prospective natural history study, CLARITY-FA, in Q2 2025 to serve as concurrent external control Phase 1/2 clinical trial of LX2020 (HEROIC-PKP2) currently enrolling patients in Cohort 3; interim clinical data update on track for second half of 2025 Redeployed $20 million to focus on clinical-stage programs; cash, cash equivalents and investments of $106.9 million expected to prov

      5/12/25 7:00:00 AM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LXEO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Cholmondeley Paula H bought $104,852 worth of shares (15,000 units at $6.99), increasing direct ownership by 96% to 30,627 units (SEC Form 4)

      4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

      11/26/24 5:00:06 PM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LXEO
    SEC Filings

    See more
    • Amendment: SEC Form S-3/A filed by Lexeo Therapeutics Inc.

      S-3/A - Lexeo Therapeutics, Inc. (0001907108) (Filer)

      6/26/25 4:56:22 PM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-3 filed by Lexeo Therapeutics Inc.

      S-3 - Lexeo Therapeutics, Inc. (0001907108) (Filer)

      6/13/25 4:09:22 PM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Lexeo Therapeutics Inc.

      DEFA14A - Lexeo Therapeutics, Inc. (0001907108) (Filer)

      6/5/25 4:52:05 PM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care